Coya Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Revenue	6	0	0
Gross Profit	6	0	0
Selling, General & Admin	7.83	4.85	2.31
Research & Development	5.5	4.41	2.54
Other Operating Expenses	0.57	0.55	0.02
Operating Expenses	13.91	9.81	4.87
Operating Income	-7.9	-9.81	-4.87
Other Expense / Income	-0.64	2.43	0.02
Pretax Income	-7.26	-12.24	-4.89
Income Tax	0.72	0	0
Net Income	-7.99	-12.24	-4.89
Shares Outstanding (Basic)	10	3	3
Shares Outstanding (Diluted)	10	3	3
Shares Change	292.40%	0.01%	-
EPS (Basic)	-0.79	-4.73	-1.89
EPS (Diluted)	-0.79	-4.73	-1.89
Free Cash Flow	-11.19	-7.24	-4.04
Free Cash Flow Per Share	-1.10	-2.79	-1.56
Gross Margin	100.00%	-	-
Operating Margin	-131.67%	-	-
Profit Margin	-133.08%	-	-
Free Cash Flow Margin	-186.41%	-	-
EBITDA	-7.24	-12.22	-4.88
EBITDA Margin	-120.57%	-	-
Depreciation & Amortization	0.03	0.03	0.02
EBIT	-7.26	-12.24	-4.89
EBIT Margin	-121.02%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).